NASDAQ:STDY SteadyMed (STDY) Stock Price, News & Analysis → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free STDY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.73▼$4.7350-Day Range N/A52-Week Range$2.60▼$6.45Volume160 shsAverage Volume85,138 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get SteadyMed alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About SteadyMedSteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology. Its lead drug product candidate is Trevyent that is used for treating pulmonary arterial hypertension. The company also develops two drug product candidates for the treatment of post-surgical and acute pain in the home setting. It has operations in Israel, the United States, and Europe. SteadyMed Ltd. was founded in 2005 and is headquartered in San Ramon, California.Read More Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! STDY Stock News HeadlinesDecember 20, 2023 | washingtonpost.comApes may remember old friends and family decades later, study saysDecember 18, 2023 | bbc.comSocial media effect 'tiny' in teenagers, large study findsApril 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.November 14, 2023 | usatoday.comShould we clean up the trash in our oceans? New study has a controversial answer.October 24, 2023 | usatoday.com'Climate captives': Frogs, salamanders and toads dying rapidly as Earth warms, study saysOctober 3, 2023 | forbes.comFluoride And IQ? What Is The Link, What This Study SaysSeptember 3, 2023 | foxnews.comBabies, young child exposed to more screen time linked with developmental delays: StudyAugust 28, 2023 | marketwatch.comCost of Owning a Dog in Every State (2023 Study)April 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.August 23, 2023 | foxnews.comMore younger people are receiving cancer diagnoses, study finds — especially this typeJuly 8, 2023 | usatoday.comClimate change fueled California's recent surge in catastrophic wildfire seasons, study saysJune 19, 2023 | usatoday.comStudy reveals how alcohol has heart benefits. Why you should still sip with caution.June 10, 2023 | usatoday.comThe sixth extinction is underway, study finds. But here's why all hope is not lost.June 2, 2023 | forbes.comBest Bar Exam Study Loans Of June 2023June 2, 2023 | usatoday.comStudy identifies symptoms that distinguish long COVID ‒ an essential step toward much-needed treatmentMay 15, 2023 | forbes.comMiss USA And Miss America Winners’ Home States May See Increase In Body Image Issues, Study ShowsMay 11, 2023 | bbc.co.ukGo The Distance: Study SkillsMay 11, 2023 | marketwatch.comWearable Injectors Market Research Provided SOWT Analysis [Latest Report] (2023-2030)May 9, 2023 | dailymail.co.ukFace masks may raise risk of stillbirths, testicular issues and cognitive decline, study saysMay 7, 2023 | usnews.comAcad of Entre Stdy@LouvertureMarch 27, 2023 | marketwatch.comWearable Injectors Market Size and Forecast till 2030March 24, 2023 | marketwatch.comWearable Injectors Market Major Players, Anlysis and Forecast till 2031March 20, 2023 | foxnews.com'Dad jokes' help kids develop into healthy adults: studyMarch 17, 2023 | nypost.comstudy saysMarch 17, 2023 | marketwatch.comSubcutaneous Infusion Systems Market Key Players and Forecast till 2028March 12, 2023 | marketwatch.comGlobal On-body Injectors Market Scenario Highlighting Key Drivers And Latest Trends 2023 – 2030 By VMReportsMarch 10, 2023 | marketwatch.comIntravenous-to-Subcutaneous Drugs Market Competitive Strategy, Trend Analysis and Forecast till 2029See More Headlines Receive STDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SteadyMed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2018Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:STDY CUSIPN/A CIK1619087 Webwww.steadymed.com Phone925-272-4999FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Jonathan M. N. Rigby (Age 50)Pres, CEO & Director Mr. David W. Nassif (Age 64)Exec. VP & CFO Mr. Robert ZwolinskiSr. VP of OperationsMs. Marylyn RigbySr. Director of Investor Relations and MarketingMr. Carl Hicks Jr.Editor & Chief of Bephenomental.comKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All Competitors STDY Stock Analysis - Frequently Asked Questions How were SteadyMed's earnings last quarter? SteadyMed Ltd. (NASDAQ:STDY) issued its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.17. What other stocks do shareholders of SteadyMed own? Based on aggregate information from My MarketBeat watchlists, some companies that other SteadyMed investors own include Amicus Therapeutics (FOLD), Fate Therapeutics (FATE), Madrigal Pharmaceuticals (MDGL), Neurocrine Biosciences (NBIX), Rigel Pharmaceuticals (RIGL), Supernus Pharmaceuticals (SUPN), Verastem (VSTM) and Biocept (BIOC). When did SteadyMed IPO? SteadyMed (STDY) raised $56 million in an initial public offering on Friday, March 20th 2015. The company issued 4,300,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager. This page (NASDAQ:STDY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SteadyMed Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
